<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Unknown</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E926C408-4F78-4E5B-BC57-E57FCC7C8C27"><gtr:id>E926C408-4F78-4E5B-BC57-E57FCC7C8C27</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Newey</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0601423"><gtr:id>B1D97C01-78B7-45C0-B443-1CF81693D4AA</gtr:id><gtr:title>Role of Parafibromin in Parathyroid Tumourigenesis and Embryonic Development</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0601423</gtr:grantReference><gtr:abstractText>Calcium plays an important role in many body processes and is the major mineral in bone. The control of body calcium is principally regulated by a hormone secreted by the parathyroids, which are located near the thyroid gland in the neck. Elevations in plasma calcium result in diminished parathyroid hormone (PTH) secretion, whereas decreases in plasma calcium result in increased PTH secretion. However, abnormalities of the parathyroids themselves will cause derangements of calcium homeostasis. Thus, PTH oversecretion i.e. hyperparathyroidism, results from parathyroid tumours (which affect 3:1,000 of the population), whilst PTH deficiency (i.e. hypoparathyroidism) often results from destruction or from a congenital failure of gland development. Hyperparathyroidism leads to a rise in plasma calcium, which may be associated with kidney stones, renal failure, osteoporosis, lethargy, nausea, vomiting, ulcers and constipation. Many hyperparathyroid disorders have a genetic basis, e.g. the Multiple Endocrine Neoplasia (MEN) syndromes, and studies of another form - the hyperparathyroidism-jaw tumour (HPT-JT) syndrome - have revealed it to be due to inactivating mutations of an oncogene, referred to as parafibromin.
I now propose to further investigate the role of this pivotal gene in the tumourigenesis pathway of the parathyroids by identifying its role and the proteins that interact with it. I will also investigate the role of this gene in embryonic development. These studies will increase our understanding of the mechanisms governing parathyroid tumour formation and help patients with this disorder.</gtr:abstractText><gtr:technicalSummary>Aims/objective:
1. Characterise the role of parafibromin in parathyroid tumour formation and early embryonic development.
2. To gain training in molecular, cellular, and developmental biology.
Background / designs:
Mutations of the gene encoding parafibromin are associated with parathyroid carcinomas and the hyperparathyroidism-jaw tumour (HPT-JT) syndrome. The functions of parafibromin remain to be defined. A mouse knockout model, in which null mice die at an early embryonic stage, has been established and 2 putative interacting proteins, TACC2 and KIF5B, identified. I therefore propose to:
1. Investigate for direct interactions between TACC2, KIF5B and parafibromin by co-immuno precipitation, GST pull-down and Far Western analysis;
2. Determine the role of parafibromin, and its interactions with proteins, in the cell cycle;
3. Identify the cause of early embryonic lethality in null mice; and 
4. Perform studies in zebrafish to elucidate the expression pattern of parafibromin in organogenesis and its signalling pathways.
Methodology:
Training in methods of molecular biology, tumour biology and developmental biology, as outlined above, plus: Southern, Northern and Western blot analysis; immuno-fluorescence immuno- histochemistry, confocal microscopy and whole-mount in situ hybridisation analysis and their use in studying altered expression in the cell cycle and in embryonic development; investigating protein - protein interactions and use of yeast two-hybrid screens; assessing the use of mouse mutant and zebrafish models; and using computer programmes for sequence analysis, protein and EST database analyses.
Scientific and medical opportunities of the study: 
Determining the role of parafibromin in: the cell cycle; cancer development in the parathyroids, kidney, uterus, and bone; and in regulating the early stages of embryonic development.</gtr:technicalSummary><gtr:fund><gtr:end>2010-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>218993</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NAAT 2011 Recorded_Research Supported from this grant led to funding from other funders</gtr:description><gtr:end>2014-02-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>CEC788D3-72E0-4FF8-8816-6C79984D6945</gtr:id><gtr:outcomeId>5277c7e674461</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>F9537F03-304C-4565-8C63-187EFAA6902F</gtr:id><gtr:title>Asymptomatic children with multiple endocrine neoplasia type 1 mutations may harbor nonfunctioning pancreatic neuroendocrine tumors.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4012bab03e044a389467d6bd29325d39"><gtr:id>4012bab03e044a389467d6bd29325d39</gtr:id><gtr:otherNames>Newey PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>8F3DE00E878</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28CDC375-15A8-46A4-A341-2C0EF151AF44</gtr:id><gtr:title>Whole-exome sequencing studies of nonhereditary (sporadic) parathyroid adenomas.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4012bab03e044a389467d6bd29325d39"><gtr:id>4012bab03e044a389467d6bd29325d39</gtr:id><gtr:otherNames>Newey PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>pm_15286_26_22855342</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0E91116F-A07A-4DC4-B824-464EF25D82D7</gtr:id><gtr:title>Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1).</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b52b61d3e3709d22522d044d591de5c9"><gtr:id>b52b61d3e3709d22522d044d591de5c9</gtr:id><gtr:otherNames>Thakker RV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>pm_15286_26_22723327</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89950FB1-8339-4586-B046-B7EECCF315EA</gtr:id><gtr:title>Role of multiple endocrine neoplasia type 1 mutational analysis in clinical practice.</gtr:title><gtr:parentPublicationTitle>Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4012bab03e044a389467d6bd29325d39"><gtr:id>4012bab03e044a389467d6bd29325d39</gtr:id><gtr:otherNames>Newey PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1530-891X</gtr:issn><gtr:outcomeId>pm_15286_26_21454234</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD2D1539-C3C1-45B1-976C-29F126EB0230</gtr:id><gtr:title>Parafibromin--functional insights.</gtr:title><gtr:parentPublicationTitle>Journal of internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4012bab03e044a389467d6bd29325d39"><gtr:id>4012bab03e044a389467d6bd29325d39</gtr:id><gtr:otherNames>Newey PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0954-6820</gtr:issn><gtr:outcomeId>E7EB1ED858E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CBA01DF6-9A9C-4420-A330-D1BA07ED9263</gtr:id><gtr:title>Cell division cycle protein 73 homolog (CDC73) mutations in the hyperparathyroidism-jaw tumor syndrome (HPT-JT) and parathyroid tumors.</gtr:title><gtr:parentPublicationTitle>Human mutation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4012bab03e044a389467d6bd29325d39"><gtr:id>4012bab03e044a389467d6bd29325d39</gtr:id><gtr:otherNames>Newey PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1059-7794</gtr:issn><gtr:outcomeId>8C7AE166BE7</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601423</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>